You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Picture Me Fit: Engaging Youth in Community-Based Prevention

    SBC: PREVENTION STRATEGIES, LLC            Topic: 600

    DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: 102

    DESCRIPTION provided by applicant In there were new cases of head and neck cancers HNC in the United States Early detection of new and locally recurrent cancers is clinically important to reduce not only cancer related mortality but also treatment associated morbidity as it impacts multiple organ functions including respiration olfaction hearing eating swallowing and speak ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Slip Flow Chromatography

    SBC: BIOVIDRIA, INC.            Topic: 100

    DESCRIPTION provided by applicant The goal of this STTR Phase II collaboration between Purdue University and bioVidria Inc is to commercialize disruptive new technology for protein chromatography and then maximize its impact by serving the fastest growing segment of the pharmaceutical industry protein drugs The product is a reversed phase chromatography column that uses silica particles of ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)

    SBC: IRON HORSE DIAGNOSTICS, INC.            Topic: 101

    DESCRIPTION provided by applicant Amyotrophic lateral sclerosis ALS or Lou Gehrigandapos s disease is a fatal neurodegenerative disease with a typical lifespan of years after diagnosis The initial symptoms can be similar to many other neurologic disorders and often begin with limb weakness muscle fasciculations or increasing difficulties in speech or breathing No definitive diagnost ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Reversal of Myocardial Infarction by Localized Stimulation

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Heart attacks i e myocardial infarction or MI occur in more than million patients annually Advances in pharmacological therapy have dramatically improved survival following the initial MI Consequently the number of patients with previous MI continues to increase and as a result put in jeopardy millions of patients for development of heart failure I ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government